Business
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with
About this update from Chemocentryx Inc.
[{"type":"text","content":"-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephrology (ASN) Kidney Week 2022 and American College of Rheumatology (ACR) Convergence 2022 annual meetings taking place in November. American Society of Nephrology Kidney Week 2022, November 3-6, Orlando Renal Recovery for Patients with Baseline eGFR ≤20 in Avacopan ADVOCATE Trial Session Title: Glomerular Diseases: Clinical, Outcomes, Trials - II Abstract Number: FR-PO651Presenter: Frank Cortazar, M.D.Date and Time: November 4, 2022, 10:00 a.m. - 12:00 p.m. ETLocation: Exhibit Hall, West Building Integrated Safety of Avacopan in ANCA-Associated Vasculitis Session Title: Glomerular Diseases: Clinical, Outcomes, Trials - III Abstract Number: SA-PO696Presenter: David Jayne, M.D.Date and Time: November 5, 2022, 10:00 a.m. - 12:00 p.m. ETLocation: Exhibit Hall, West Building Kidney C5aR is Expressed in Resident Macrophages, Tubular Epithelial Cells, and in Association with Fibrosis Session Title: Glomerular Diseases: IgA and Complement-Mediated GN Abstract Number: SA-PO633Presenter: Carolyn DunlapDate and Time: November 5, 2022, 10:00 a.m. - 12:00 p.m. ETLocation: Exhibit Hall, West Building ASN Kidney Week posters are viewable as ePosters during the entire conference for conference registrants. American College of Rheumatology Convergence 2022, November 10-14, PhiladelphiaRecovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR ≤20 in the Avacopan ADVOCATE Trial Session Title: Abstracts: Vasculitis – ANCA-AssociatedAbstract Number: 525Presenter: Frank Cortazar, M.D.Oral Presentation Date and Time: November 12, 2022, 3:15 - 3:25 p.m. ETLocation: Room 103 ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain Session Title: Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, BiomarkersAbstract Number: 1076Presente...